Julie Krop - 01 Jun 2026 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Reporting relationship: Chief Medical Officer
Issuer ticker: DMAC
Reported as of: 01 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2026, 17:22:33 UTC
Prior SEC filing: 03 Nov 2025
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Joshua L. Colburn, attorney-in-fact

Key filing fact

Julie Krop filed Form 4 for DiaMedica Therapeutics Inc. (DMAC) on 03 Jun 2026.

Key facts

This page summarizes Julie Krop's Form 4 filing for DiaMedica Therapeutics Inc. (DMAC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2026, 17:22.

Change

Previous filing in this sequence was filed on 03 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001643127 Primary reporting owner

Krop Julie

Relationship: Chief Medical Officer
Address: 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS
Signature: /s/ Joshua L. Colburn, attorney-in-fact
Signature date: 03 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DMAC transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +67,500
Change %
Price: $0.000000^*
Shares after: 67,500
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Voting Common Shares
Underlying amount: 67,500
Exercise price: $5.84
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Scheduled to vest with respect to 25% of the shares on the one-year anniversary of the grant date, with the remaining shares scheduled to vest in twelve equivalent quarterly installments.